A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
NCT02613221
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Panitumumab + TAS-102
Sponsor
Takeda